Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | YWHAG | P61981 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17320655 | 0.82 | ALOX5 (0.55) | ALOX15PTPN1ALOX5KDM4EHSD17B10 | |
| SCHEMBL4858133 | 0.82 | RAB9A (0.36) | KDM1AKDM1BRAB9AMEN1KMT2A | |
| SCHEMBL24574628 | 0.78 | CYP3A4 (0.42) | ALOX15PTPN1SIRT1KDM4ECASP1 | |
| SCHEMBL2856571 | 0.77 | TP53 (0.41) | ALDH1A1SMN1; SMN2TSHRRAB9AMEN1 | |
| SCHEMBL5791363 | 0.77 | ABCC9 (0.35) | RAB9AMEN1KMT2AHTT | |
| SCHEMBL3711765 | 0.77 | ABCC9 (0.44) | MEN1KMT2A | |
| SCHEMBL242386 | 0.77 | DRD3 (0.47) | ALOX15PTPN1ALOX5KDM4EHSD17B10 | |
| SCHEMBL8010373 | 0.77 | ALOX5 (0.38) | PTPN1ALOX5YWHAGRAB9AMEN1 | |
| SCHEMBL3695721 | 0.77 | HSD17B10 (0.43) | ESR1ESR2PTPN1ALOX5SIRT1 | |
| SCHEMBL3695981 | 0.77 | ESR1 (0.43) | ESR1ESR2PTPN1ALOX5SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946287-B2 | Chemotherapeutic flavonoids, and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946287-B2 | Chemotherapeutic flavonoids, and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| EP-2254855-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| US-20100099755-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099755-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2009098287-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098287-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008076767-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076767-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2008-06-26 | — | — | WO | disclosed |
| US-5716971-A | FOR TREATMENT OF ANGINA PECTORIS AND HYPERTENSION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0623597-B1 | Pyridine derivatives, with potassium channel opening activity | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-22 | — | — | EP | disclosed |
| EP-0623597-A1 | Pyridine derivatives, with potassium channel opening activity | Takeda Chemical Industries, Ltd. (JP) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099755-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | NRAS, FAU, DPYD | ALOX15 3083/4885ESR1 1627/4885ESR2 2788/4885 |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PSEN1, PARK7, APP | ALOX15 308/4885ESR1 3852/4885ESR2 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.